An Exploratory phase II Study of Eribrin rechallenge after short term therapy of 5-FU for HER2 negative, advanced/recurrent breast cancer.
Phase of Trial: Phase II
Latest Information Update: 18 May 2016
At a glance
- Drugs Eribulin (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 21 Oct 2015 New trial record